Human antibodies that bind human TNFα
Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d =10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
1. A method of treating a human subject having an inflammatory bowel disease, said method comprising administering an isolated human anti-TNFα antibody, or an antigen-binding portion thereof, to the subject, wherein the antibody, or antigen-binding portion thereof, comprises
a light chain variable region (LCVR) comprising a complementarity determining region 3 (CDR3) domain comprising the amino acid sequence as set forth in SEQ ID NO: 3, or modified from SEQ ID NO: 3 by a single alanine substitution at position 1, 4, 5, 7 or 8, a CDR2 domain comprising the amino acid sequence as set forth in SEQ ID NO: 5, and a CDR1 domain comprising the amino acid sequence as set forth in SEQ ID NO: 7,
a heavy chain variable region (HCVR) comprising a CDR3 domain comprising the amino acid sequence as set forth in SEQ ID NO: 4, or modified from SEQ ID NO: 4 by a single alanine substitution at position 2, 3, 4, 5, 6, 8, 9, 10 or 11, a CDR2 domain comprising the amino acid sequence as set forth in SEQ ID NO: 6, and a CDR1 domain comprising the amino acid sequence as set forth in SEQ ID NO: 8, and
an IgG1 or an IgG4 heavy chain constant region.
2. The method of claim 1 , wherein the inflammatory bowel disease is Crohn's disease.
3. The method of claim 1 , wherein the inflammatory bowel disease is ulcerative colitis.
4. The method of claim 1 , wherein the antibody, or antigen binding portion thereof, comprises an IgG1 heavy chain constant region.
5. A method of treating a human subject having an inflammatory bowel disease, said method comprising administering an isolated human anti-TNFα antibody, or an antigen-binding portion thereof, to the subject, wherein the antibody, or antigen-binding portion thereof, comprises
a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1,
a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2,
an IgG1 heavy chain constant region, and
a kappa light chain constant region.
6. The method of claim 5 , wherein the inflammatory bowel disease is Crohn's disease.
7. The method of claim 5 , wherein the inflammatory bowel disease is ulcerative colitis.